himachalol
Description
Himachalol is a natural product isolated from the bark of the Himalayan yew tree (Taxus wallichiana). It exhibits significant biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Its synthesis has been studied extensively, and several methods have been developed. Himachalol is particularly interesting due to its potential as a therapeutic agent, and researchers are investigating its mechanisms of action and its efficacy in treating various diseases. Its unique structure and biological activity make it an attractive target for drug discovery.'
himachalol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 121536 |
| CHEBI ID | 5719 |
| SCHEMBL ID | 2854768 |
| MeSH ID | M0055506 |
Synonyms (15)
| Synonym |
|---|
| 11alpha-himachal-4-en-11-ol |
| CHEBI:5719 |
| 2,4a-beta,5,6,7,8,9,9a-beta-octahydro-3,5,5,9-beta-tetramethyl-1h-benzocyclohepten-9-ol |
| 1h-benzocyclohepten-9-ol, 2,4a-beta,5,6,7,8,9,9a-beta-octahydro-3,5,5,9-beta-tetramethyl- |
| (4ar,5r,9as)-2,5,9,9-tetramethyl-4,4a,6,7,8,9a-hexahydro-3h-benzo[7]annulen-5-ol |
| 2,4a,5,6,7,8,9,9a-octahydro-3,5,5,9-tetramethyl-1h-benzocyclohepten-9-ol |
| 1891-45-8 |
| himachalol |
| C09682 |
| LMPR0103480003 |
| (+)-2-himachalen-7-ol |
| SCHEMBL2854768 |
| 3,5,5,9-tetramethyl-2,4a,5,6,7,8,9,9a-octahydro-1h-benzo[7]annulen-9-ol |
| DTXSID70940424 |
| Q27106868 |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Himachalol has been identified as the major antispasmodic constituent in the wood of Cedrus deodara. " | ( Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol. Dhawan, BN; Kar, K; Kulshrestha, DK; Patnaik, GK; Puri, VN; Rastogi, RP; Sur, RN, 1975) | 1.92 |
Drug Classes (1)
| Class | Description |
|---|---|
| himachalane sesquiterpenoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.86
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.86) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||